Pliant Therapeutics Inc
Pliant Therapeutics (PLRX) is a clinical‑stage biotechnology company focused on developing therapies for fibrotic diseases. With a market capitalisation around $115m, it sits in the small‑cap, high‑volatility segment of healthcare. Investors should know the company’s value is driven largely by clinical progress and trial readouts rather than current revenues; successful trial data or partnerships can be significant catalysts, while negative results or funding shortfalls can materially depress the share price. Typical risks include long development timelines, regulatory uncertainty, potential dilution from future financings and the binary nature of clinical outcomes. This summary is for educational purposes and not investment advice — investors should review regulatory filings, recent trial updates, cash runway and analyst commentary, and consider suitability with their objectives and risk tolerance before making decisions.
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Pliant Therapeutics' stock with a target price of $41.08, indicating potential growth.
Financial Health
Pliant Therapeutics is performing adequately in terms of cash flow and book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring PLRX
The Plasma Profit Pipeline
Biopharmaceutical leader CSL reported a 14% surge in annual profit, fueled by its plasma division's success. This highlights a growing investment opportunity in companies involved in the plasma-derived therapies market and the broader bioprocessing supply chain.
Published: August 19, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical‑stage focus
Programmes are at the clinical development stage, so trial readouts and regulatory steps are key catalysts — though results can be binary and unpredictable.
Fibrosis market potential
Fibrotic diseases represent a significant unmet medical need, offering potential upside if therapies prove effective, while commercial success is far from guaranteed.
Capital and timing
As a small‑cap company with a market cap ~ $115m, funding rounds and partnerships can change the outlook; investors should consider runway and dilution risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
AbbVie Inc.
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
Amgen Inc.
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
ADMA BIOLOGICS INC
Develops products to treat immune deficiencies and chronic diseases.
